Do analysts recommend ABDX or DXRX?

Diaceutics has a consensus price target of GBX 215, indicating a potential upside of 11.40%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Abingdon Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abingdon Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend DXRX or GDR?

Diaceutics currently has a consensus price target of GBX 215, suggesting a potential upside of 11.40%. Given Diaceutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Diaceutics is more favorable than genedrive. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 genedrive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, DXRX or GDR?

Diaceutics has higher revenue and earnings than genedrive. Diaceutics is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Diaceutics £41.33M 3.96 -£2.84M -£0.32 N/A genedrive £929K 20.51 -£21.22M -£0.79 N/A

Is DXRX or GDR more profitable?

Diaceutics has a net margin of -0.66% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of -0.68% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets Diaceutics -0.66% -0.68% -6.06% genedrive -500.75% -1,044.57% -74.09%

Do analysts rate YGEN or DXRX?

Diaceutics has a consensus target price of GBX 215, suggesting a potential upside of 11.40%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than Yourgene Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yourgene Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate DXRX or AGL?

Diaceutics currently has a consensus price target of GBX 215, suggesting a potential upside of 11.40%. Given Diaceutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Diaceutics is more favorable than ANGLE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 ANGLE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, DXRX or AGL?

Diaceutics has higher revenue and earnings than ANGLE. Diaceutics is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Diaceutics £41.33M 3.96 -£2.84M -£0.32 N/A ANGLE £2.62M 2.89 -£21.76M -£4.80 N/A

Is DXRX or AGL more profitable?

Diaceutics has a net margin of -0.66% compared to ANGLE's net margin of -1,444.04%. Diaceutics' return on equity of -0.68% beat ANGLE's return on equity. Company Net Margins Return on Equity Return on Assets Diaceutics -0.66% -0.68% -6.06% ANGLE -1,444.04% -191.36% -29.89%

Do analysts prefer DXRX or GENI?

Diaceutics currently has a consensus target price of GBX 215, indicating a potential upside of 11.40%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts plainly believe Diaceutics is more favorable than GENinCode. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 GENinCode 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is DXRX or GENI more profitable?

Diaceutics has a net margin of -0.66% compared to GENinCode's net margin of -202.42%. Diaceutics' return on equity of -0.68% beat GENinCode's return on equity. Company Net Margins Return on Equity Return on Assets Diaceutics -0.66% -0.68% -6.06% GENinCode -202.42% -481.34% -63.99%

Diaceutics (DXRX) Competitors

GBX 199.50 +6.50 (+3.37%)

As of 11:59 AM Eastern

Compare

DXRX vs. ABDX, GDR, YGEN, AGL, and GENI

Should you buy Diaceutics stock or one of its competitors? Diaceutics's main competitors and comparable companies include Abingdon Health (ABDX), genedrive (GDR), Yourgene Health (YGEN), ANGLE (AGL), and GENinCode (GENI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Diaceutics compare to Abingdon Health?

Abingdon Health (LON:ABDX) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Abingdon Health has higher earnings, but lower revenue than Diaceutics. Diaceutics is trading at a lower price-to-earnings ratio than Abingdon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abingdon Health	£9.57M	2.79	-£796.37K	-£0.81	N/A
Diaceutics	£41.33M	3.96	-£2.84M	-£0.32	N/A

Diaceutics has a consensus price target of GBX 215, indicating a potential upside of 11.40%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Abingdon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abingdon Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Diaceutics has a net margin of -0.66% compared to Abingdon Health's net margin of -33.88%. Diaceutics' return on equity of -0.68% beat Abingdon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abingdon Health	-33.88%	-55.91%	-17.93%
Diaceutics	-0.66%	-0.68%	-6.06%

In the previous week, Abingdon Health had 1 more articles in the media than Diaceutics. MarketBeat recorded 1 mentions for Abingdon Health and 0 mentions for Diaceutics. Abingdon Health's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company	Overall Sentiment
Abingdon Health	Neutral
Diaceutics	Neutral

Abingdon Health has a beta of 0.132, indicating that its stock price is 87% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.884, indicating that its stock price is 12% less volatile than the broader market.

3.7% of Abingdon Health shares are owned by institutional investors. Comparatively, 26.9% of Diaceutics shares are owned by institutional investors. 8.0% of Abingdon Health shares are owned by insiders. Comparatively, 26.3% of Diaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Diaceutics beats Abingdon Health on 12 of the 15 factors compared between the two stocks.

How does Diaceutics compare to genedrive?

Diaceutics (LON:DXRX) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

In the previous week, Diaceutics' average media sentiment score of 0.00 equaled genedrive'saverage media sentiment score.

Company	Overall Sentiment
Diaceutics	Neutral
genedrive	Neutral

Diaceutics currently has a consensus price target of GBX 215, suggesting a potential upside of 11.40%. Given Diaceutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Diaceutics is more favorable than genedrive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
genedrive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

26.9% of Diaceutics shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 26.3% of Diaceutics shares are held by insiders. Comparatively, 28.1% of genedrive shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Diaceutics has higher revenue and earnings than genedrive. Diaceutics is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£41.33M	3.96	-£2.84M	-£0.32	N/A
genedrive	£929K	20.51	-£21.22M	-£0.79	N/A

Diaceutics has a beta of 0.884, suggesting that its share price is 12% less volatile than the broader market. Comparatively, genedrive has a beta of 0.968, suggesting that its share price is 3% less volatile than the broader market.

Diaceutics has a net margin of -0.66% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of -0.68% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	-0.66%	-0.68%	-6.06%
genedrive	-500.75%	-1,044.57%	-74.09%

Summary

Diaceutics beats genedrive on 10 of the 14 factors compared between the two stocks.

How does Diaceutics compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

23.3% of Yourgene Health shares are held by institutional investors. Comparatively, 26.9% of Diaceutics shares are held by institutional investors. 64.4% of Yourgene Health shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Diaceutics has higher revenue and earnings than Yourgene Health. Diaceutics is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A
Diaceutics	£41.33M	3.96	-£2.84M	-£0.32	N/A

Diaceutics has a net margin of -0.66% compared to Yourgene Health's net margin of -27.55%. Diaceutics' return on equity of -0.68% beat Yourgene Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yourgene Health	-27.55%	-27.06%	-6.71%
Diaceutics	-0.66%	-0.68%	-6.06%

Diaceutics has a consensus target price of GBX 215, suggesting a potential upside of 11.40%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than Yourgene Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yourgene Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Yourgene Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.884, meaning that its stock price is 12% less volatile than the broader market.

In the previous week, Yourgene Health's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company	Overall Sentiment
Yourgene Health	Neutral
Diaceutics	Neutral

Summary

Diaceutics beats Yourgene Health on 10 of the 13 factors compared between the two stocks.

How does Diaceutics compare to ANGLE?

Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Diaceutics has a net margin of -0.66% compared to ANGLE's net margin of -1,444.04%. Diaceutics' return on equity of -0.68% beat ANGLE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	-0.66%	-0.68%	-6.06%
ANGLE	-1,444.04%	-191.36%	-29.89%

In the previous week, ANGLE had 1 more articles in the media than Diaceutics. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for Diaceutics. ANGLE's average media sentiment score of 0.75 beat Diaceutics' score of 0.00 indicating that ANGLE is being referred to more favorably in the news media.

Company	Overall Sentiment
Diaceutics	Neutral
ANGLE	Positive

Diaceutics currently has a consensus price target of GBX 215, suggesting a potential upside of 11.40%. Given Diaceutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Diaceutics is more favorable than ANGLE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
ANGLE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Diaceutics has a beta of 0.884, meaning that its share price is 12% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

Diaceutics has higher revenue and earnings than ANGLE. Diaceutics is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£41.33M	3.96	-£2.84M	-£0.32	N/A
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A

26.9% of Diaceutics shares are held by institutional investors. Comparatively, 17.5% of ANGLE shares are held by institutional investors. 26.3% of Diaceutics shares are held by insiders. Comparatively, 2.7% of ANGLE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Diaceutics beats ANGLE on 13 of the 16 factors compared between the two stocks.

How does Diaceutics compare to GENinCode?

Diaceutics (LON:DXRX) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

In the previous week, GENinCode had 5 more articles in the media than Diaceutics. MarketBeat recorded 5 mentions for GENinCode and 0 mentions for Diaceutics. Diaceutics' average media sentiment score of 0.00 beat GENinCode's score of -0.31 indicating that Diaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
Diaceutics	Neutral
GENinCode	Neutral

Diaceutics has higher revenue and earnings than GENinCode. Diaceutics is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£41.33M	3.96	-£2.84M	-£0.32	N/A
GENinCode	£3.08M	1.76	-£6.10M	-£2.08	N/A

26.9% of Diaceutics shares are owned by institutional investors. Comparatively, 11.4% of GENinCode shares are owned by institutional investors. 26.3% of Diaceutics shares are owned by company insiders. Comparatively, 8.4% of GENinCode shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Diaceutics has a net margin of -0.66% compared to GENinCode's net margin of -202.42%. Diaceutics' return on equity of -0.68% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	-0.66%	-0.68%	-6.06%
GENinCode	-202.42%	-481.34%	-63.99%

Diaceutics has a beta of 0.884, suggesting that its share price is 12% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Diaceutics currently has a consensus target price of GBX 215, indicating a potential upside of 11.40%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts plainly believe Diaceutics is more favorable than GENinCode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
GENinCode	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Diaceutics beats GENinCode on 14 of the 16 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXRX vs. The Competition

Export

Metric	Diaceutics	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£169.30M	£10.67B	£7.10B	£2.83B
Dividend Yield	N/A	1.45%	2.54%	6.26%
P/E Ratio	-623.44	31.77	273.67	366.32
Price / Sales	4.10	107.59	595.47	89,071.63
Price / Cash	3.12	27.32	27.22	27.89
Price / Book	4.35	6.79	11.09	6.96
Net Income	-£2.84M	£57.48B	£3.49B	£5.89B
7 Day Performance	3.91%	-0.37%	-2.28%	-0.62%
1 Month Performance	33.00%	6.90%	-7.03%	-1.07%
1 Year Performance	20.53%	29.21%	5.66%	22.84%

Diaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXRX Diaceutics	N/A	GBX 199.50 +3.4%	GBX 215 +7.8%	+16.3%	£169.30M	£41.33M	N/A	151	High Trading Volume
ABDX Abingdon Health	N/A	GBX 10.57 -3.9%	N/A	+75.0%	£27.80M	£9.57M	N/A	84	Gap Down
GDR genedrive	N/A	GBX 1.16 -3.3%	N/A	+405.1%	£18.87M	£929K	N/A	43	Gap Up
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253
AGL ANGLE	N/A	GBX 2.35 -11.3%	N/A	-14.5%	£7.58M	£2.62M	N/A	650	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:DXRX) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Diaceutics (DXRX) Competitors

DXRX vs. ABDX, GDR, YGEN, AGL, and GENI

How does Diaceutics compare to Abingdon Health?

Summary

How does Diaceutics compare to genedrive?

Summary

How does Diaceutics compare to Yourgene Health?

Summary

How does Diaceutics compare to ANGLE?

Summary

How does Diaceutics compare to GENinCode?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Diaceutics (DXRX) Competitors

DXRX vs. ABDX, GDR, YGEN, AGL, and GENI

How does Diaceutics compare to Abingdon Health?

Which has preferable valuation & earnings, ABDX or DXRX?

Do analysts recommend ABDX or DXRX?

Is ABDX or DXRX more profitable?

Does the media refer more to ABDX or DXRX?

Which has more volatility and risk, ABDX or DXRX?

Do insiders and institutionals have more ownership in ABDX or DXRX?

Summary

How does Diaceutics compare to genedrive?

Does the media prefer DXRX or GDR?

Do analysts recommend DXRX or GDR?

Do insiders & institutionals believe in DXRX or GDR?

Which has better earnings & valuation, DXRX or GDR?

Which has more volatility & risk, DXRX or GDR?

Is DXRX or GDR more profitable?

Summary

How does Diaceutics compare to Yourgene Health?

Do insiders and institutionals believe in YGEN or DXRX?

Which has better valuation and earnings, YGEN or DXRX?

Is YGEN or DXRX more profitable?

Do analysts rate YGEN or DXRX?

Which has more volatility & risk, YGEN or DXRX?

Does the media refer more to YGEN or DXRX?

Summary

How does Diaceutics compare to ANGLE?

Is DXRX or AGL more profitable?

Does the media refer more to DXRX or AGL?

Do analysts rate DXRX or AGL?

Which has more risk and volatility, DXRX or AGL?

Which has higher earnings & valuation, DXRX or AGL?

Do insiders & institutionals believe in DXRX or AGL?

Summary

How does Diaceutics compare to GENinCode?

Does the media prefer DXRX or GENI?

Which has stronger earnings & valuation, DXRX or GENI?

Do institutionals and insiders believe in DXRX or GENI?

Is DXRX or GENI more profitable?

Which has more volatility & risk, DXRX or GENI?

Do analysts prefer DXRX or GENI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools